Accessibility Menu
Acadia Pharmaceuticals logo

Acadia Pharmaceuticals(NASDAQ) ACAD

Current Price$24.82
Market Cap$4.25BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2004)+271%
5 Year+16%
1 Year+7%
1 Month+10%
Acadia Pharmaceuticals last closing stock price
MetricPriceDate
Last closeUSD 24.832026-07-23
Acadia Pharmaceuticals stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-3.12%USD 25.632026-07-16
1 month+9.87%USD 22.602026-06-23
3 month+13.07%USD 21.962026-04-24
Year to date-7.04%USD 26.712025-12-31
1 year+6.7%USD 23.272025-07-23
3 year-17.29%USD 30.022023-07-24
5 year+15.7%USD 21.462021-07-23
Since inception+270.6%USD 6.702004-05-27

Acadia Pharmaceuticals Financials at a Glance

Market Cap

$4.25BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$1.10B

Net Income (TTM)

$375.65M

EPS (TTM)

$2.20

P/E Ratio

11.31

Dividend

$0.00

Beta (Volatility)

0.95 (Low)

Price

$24.82

Volume

1,046,975

Open

$24.90

Previous Close

$24.84

Daily Range

$24.57 - $25.10

52-Week Range

$19.69 - $28.35

Estimated Earnings Date

Aug 4, 2026

ACAD News

SellAlert-Green.png

An Acadia Pharmaceuticals Insider Sold Nearly Half Their Shares in the Company. What Does That Mean for Investors?

Robert IzquierdoJul 11, 2026
BuyAlert-Red.png

Acadia Stock Up 59% in a Year — Is a $51 Million New Stake a Bet on a Bigger Rebound?

Jonathan PoncianoDec 3, 2025
Foolcom-Featured.png

Acadia (ACAD) Q2 Revenue Rises 9%

Motley Fool Markets TeamAug 6, 2025
growth curve

Why Acadia Pharmaceuticals Stock Is Rising Today

George Budwell, PhDOct 10, 2023
u turn

2 Growth Stocks I'd Buy on the Dip

George Budwell, PhDSep 30, 2023
growth

2 Supercharged Growth Stocks Billionaires Can't Stop Buying

George Budwell, PhDAug 28, 2023
biotech researcher

Can This Red-Hot Biotech Stock Keep Beating the Broader Markets?

George Budwell, PhDAug 22, 2023
Biotech scientist-microscope-getty

Why These 2 Biotech Stocks Made Big Moves Late Thursday

Dan CaplingerJul 13, 2023
Page 1

ACAD: Motley Fool Moneyball Superscore

67

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Acadia Pharmaceuticals

Acadia helps people with rare brain diseases and neurological conditions. It makes medicines for those suffering from hallucinations or developmental delays. These treatments aim to improve daily life for patients and their caregivers.

What Acadia Makes

  • NUPLAZID: Prescription medicine used to treat hallucinations and delusions in people with Parkinson's disease psychosis; it targets specific serotonin receptors in the brain.
  • DAYBUE: First approved treatment for Rett syndrome, a rare genetic disorder that affects brain development in children and adults.
  • DAYBUE STIX: New powder version of the Rett syndrome treatment designed to give patients more choice in how they take their medicine.
  • Pipeline Programs: Research projects testing new drugs for conditions like Alzheimer's disease psychosis, Lewy Body Dementia, and major depressive disorder.

New Moves and Partnerships

  • Acquired an exclusive North American license for trofinetide from Neuren Pharmaceuticals Limited in August 2018.
  • Expanded the Neuren Pharmaceuticals Limited agreement in July 2023 to gain global rights for trofinetide and the new candidate ACP-2591.
  • Partnered with Stoke Therapeutics in January 2022 to discover RNA-based medicines for rare genetic brain diseases.
  • Entered an exclusive worldwide license agreement with Saniona A/S in November 2024 to develop a treatment for essential tremor.
  • Sold a Rare Pediatric Disease Priority Review Voucher in December 2024 for $150 million.

How the Company Stands Out

Acadia focuses on precision medicine by using targeted biological markers to increase the success rate of new drug trials. The company uses artificial intelligence and machine learning to analyze data more efficiently from the discovery phase through to patient sales.

The Recent Numbers

  • Net product sales reached $1.07 billion in 2025, up 11.9% from $957.8 million in 2024.
  • Net income rose to $273.6 million in Q4 2025, up 90.3% year-over-year.
  • Revenue grew to $284 million in Q4 2025, a 9.4% increase from $259.6 million in Q4 2024.
  • Operating income dropped to $17.4 million in Q4 2025, down 88.7% from $153.5 million in Q4 2024.
  • Free cash flow fell to negative $52.7 million in Q4 2025, down 232.1% from $39.9 million in Q4 2024.

The Evolution of Acadia

Acadia has transitioned from a research-focused firm into a commercial biopharmaceutical company with two major products on the market. By expanding its pipeline and moving into global markets like Europe and Japan, the company continues to focus on unmet medical needs in the neurological space.

AI Generated • Apr 24, 2026

Industry

Biotechnology

Sector

Health Care

Employees

798

CEO

Catherine Owen Adams

Website

www.acadia.com

Headquarters

San Diego, CA 92130, US

ACAD Financials

Key Financial Metrics (TTM)

Gross Margin

91.47%

Operating Margin

7.39%

Net Income Margin

34.30%

Return on Equity

35.65%

Return on Capital

8.19%

Return on Assets

23.40%

Earnings Yield

8.84%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$4.25BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

171.24M

Volume

1.05M

Avg. Volume

1.61M

Financials (TTM)

Gross Profit

$1.00B

Operating Income

$80.91M

EBITDA

$126.91M

Operating Cash Flow

$123.49M

Capital Expenditure

$88.94M

Free Cash Flow

$212.43M

Cash & ST Invst.

$851.46M

Total Debt

$50.79M

Acadia Pharmaceuticals Performance Analysis

Acadia Pharmaceuticals annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 517,235,0006.8%
20232023-12-31USD 726,437,00040.4%
20242024-12-31USD 957,797,00031.8%
20252025-12-31USD 1,071,505,00011.9%
Acadia Pharmaceuticals sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-308.3%
Q32025-09-305.3%
Q42025-12-311.9%
Q12026-03-31-5.6%
Acadia Pharmaceuticals annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -1.3427.7%
20232023-12-31USD -0.37-72.0%
20242024-12-31USD 1.36N/A
20252025-12-31USD 2.3069.0%
Acadia Pharmaceuticals sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3045.5%
Q32025-09-30162.5%
Q42025-12-31281.0%
Q12026-03-31-98.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$268.06M

+9.7%

Gross Profit

$243.27M

+8.6%

Gross Margin

90.75%

N/A

Market Cap

$4.25BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$5.33M

N/A

Employees

798

N/A

Net Income

$3.64M

-80.8%

EBITDA

$6.97M

-77.3%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$851.46M

+24.9%

Total Debt

$50.79M

-9.3%

Accounts Receivable

$148.38M

+30.5%

Inventory

$31.57M

+37.6%

Long Term Debt

$39.00M

-12.6%

Short Term Debt

$11.79M

+3.7%

Return on Assets

23.40%

N/A

Return on Invested Capital

6.22%

N/A

Free Cash Flow

$28.77M

+136.6%

Operating Cash Flow

$33.98M

+67.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
DYNDyne Therapeutics, Inc.
$24.44+2.30%
VKTXViking Therapeutics, Inc.
$34.79-1.70%
MIRMMirum Pharmaceuticals, Inc.
$113.03-1.16%
SLNOSoleno Therapeutics, Inc.
$53.01+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.42-0.04%
ONDSOndas
$7.80-0.02%
SOFISoFi Technologies
$16.46-0.01%
FFord Motor Company
$14.37+0.02%

Questions About ACAD

What is the current price of Acadia Pharmaceuticals?

Acadia Pharmaceuticals is trading at $24.84 per share.

What is the 52-week range for Acadia Pharmaceuticals?

Over the past 52 weeks, Acadia Pharmaceuticals has traded between $19.69 and $28.35.

How much debt does Acadia Pharmaceuticals have?

As of the most recent reporting period, Acadia Pharmaceuticals reported total debt of $50.79M.

How much cash does Acadia Pharmaceuticals have on hand?

Acadia Pharmaceuticals reported $282.21M in cash and cash equivalents in its most recent financial results.

What is Acadia Pharmaceuticals’s dividend yield?

Acadia Pharmaceuticals does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services